Japan’s Sosei (TYO: 4565) has announced that it will not take up an option to acquire more equity in MiNA Therapeutics, the British RNA activation therapeutics company.
Sosei explained the decision was made based on a rigorous analysis of interim data from MiNA’s Phase I/IIa OUTREACH study of MTL-CEPBA in hepatocellular carcinoma, as well as the “prioritization of resources directed towards other opportunities.”
The firm’s chief R&D officer, Malcolm Weir, said: “Our strategic investment in MiNA gave us an early option on a novel technology platform to enhance our pipeline. We noted some interesting findings from the interim clinical data, as well as subsequent observations with respect to the potential to combine MTL-CEBPA with other oncology drugs.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze